103 results about "Cancer stem cell" patented technology

Provided herein are methods and compositions for treating chordoma by preferentially targeting cancer stem cells than non-cancer stem cells in chordoma to effectively treat chordoma. In some embodiments, the chordoma tumors cells (preferentially the cancer stem cells in chordoma) are targeted by modified NK-92 cells (i.e., haNK® cells) that express CARs that comprise means for binding to the PD-L1 and another tumor-specific antigen (e.g., EGFR). In some embodiments, the chordoma tumor cells are targeted by using NK cells in combination with a means for binding to means for binding to the PD-L1 and / or a means for binding another tumor antigen (e.g., EGFR). Each of the treatment methods disclosed above may be implemented prior to, and / or concurrent with radio- and / or chemotherapy, and / or may be employed with immune therapy as is discussed in more detail below.

The present invention is in the field of oncology, and more particularly of cancer stem cells. It relates to a method for producing cancer stem cells based on overexpression of Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms; a method for predicting the risk that treatment with a chemotherapeutic anti-cancer agent induces cancer stem cells in a subject suffering from cancer from a cancer sample of said subject, based on detection of an increase in Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms following chemotherapeutic anti-cancer treatment; to therapeutic uses of a combination of chemotherapeutic anti-cancer agent and an agent reducing Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms expression; and also to screening methods for anti-cancer stem cells agents.

The present invention provides a compound with which a molecular probe capable of distinguishing NSCs from CSCs can be produced, and a method for detecting cancer stem cells using the compound. The present invention relates to a compound having a formyl group, a substrate moiety, a quenching moiety, and a luminescent moiety that is non-luminous due to the quenching moiety, wherein the luminescent moiety may be rendered luminous by detaching the substrate moiety by a substrate-degrading enzyme and also converting the formyl group to a carboxy group by an aldehyde dehydrogenase to allow the quenching moiety to dissociate.

The present invention relates to aptamers that specifically bind to the extra-cellular domain of alpha7 / beta1 integrin dimers, conjugates or particles comprising said aptamers, in muscles cells such as skeletal muscle fibres and satellite cells, or in cells aberrantly expressing said domain e.g. tumour cells such as rhabdomyosarcoma (muscle-derived tumours), or glioblastoma cancer stem cells, as well as conjugates comprising said aptamers, therapeutic or diagnostic compositions comprising said conjugates or said aptamers, and their use as a medicament and in diagnostic methods.

Disclosed are 1,2,4,5-tetraoxane compounds and derivatives thereof having anticancer properties. Disclosed are pharmaceutical compositions and pharmaceutical formulations in unit dosage form suitable for delivering the compounds to a subject in need thereof. In addition to the compounds, the pharmaceutical compositions or formulations can include one or more active agents, such as one or more additional anticancer agents. Also disclosed are methods of treating, mitigating, or treating or ameliorating one or more symptoms associated with cancer in a subject. The methods include (i) administering to a subject in need thereof an effective amount of a compound. The compound can be administered by oral administration, parenteral administration, inhalation, mucosal administration, or a combination thereof. The compound can selectively kill cancer cells and / or cancer stem cells, but not non-cancer cells, by inducing ferroptosis in the cancer cells and / or cancer stem cells.

This invention provides a method for diagnosing or treating cancerous diseases that contains cancer stem cells. [Solution] A method for measuring cancer stem cells is provided, comprising detecting cells expressing CLDN6. In particular, the present invention provides a method for measuring cancer stem cells, comprising detecting cells expressing CLDN6. Furthermore, the present invention provides a method for treating or preventing cancer, comprising inhibiting and / or eliminating cancer stem cells by administering an antibody having the ability to bind to CLDN6 to a cancer patient.

Provided herein are methods of detecting an aggression level of a glioblastoma in a subject. In some embodiments, the methods include imaging the subject having the glioblastoma using a CEST MRI technique in the absence of introducing an exogenous MRI contrast agent into the subject to produce a test MR image of the subject. In some embodiments, the methods also include identifying an overexpression level of mannose in and / or on surfaces of unlabeled cancer stem cells of the glioblastoma of the subject in the test MR image relative to an identified expression level of mannose in and / or on surfaces of brain cells in a control MR image, wherein a high aggression level is indicated when the overexpression level comprises at least about a 1.8-fold difference and wherein a low aggression level is indicated when the overexpression level comprises less than about a 1.8-fold difference. Related aspects are also provided.

Provided are methods relating to SIRPgamma as a biomarker for cancer cells, and in particular of cancer stem cells and lung adenocarcinoma. Disclosed are also methods of treatment, which involve administering a SIRPgamma targeted agent to a subject with cancer, alone or with another cancer therapy. Methods for diagnosing cancer, identifying subjects with high SIRPgamma levels for treatment, and monitoring SIRPgamma expressing tumors are also provided.

The present invention provides methods and kits a) for preventing and / or treating neuroblastoma (e.g., high-risk neuroblastoma) that is linked, in part, to high levels of ODC activity and increased cellular polyamine content, b) for predicting cancer patient survival, especially cancer patients whose cancer is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and c) for selecting treatment options for such patients based on the allelic nucleotide sequence or SNP at positions +263 and / or +316 of the ODC1 gene. The invention also provides, cancer treatment methods comprising the determination of the ODC1 genotype at the +263 and / or +316 positions, as a means to guide treatment selection, which includes, in some aspects the administration of pharmaceutically effective amounts of α-difluoromethylornithine (DFMO), either as a monotherapy or in combination with one or more other drugs. In addition, the present invention provides methods for preventing and / or treating patients that have been determined to have cancer stem cells, such as patients in cancer remission that are at risk for relapse.

Provided herein are methods of detecting an aggression level of a glioblastoma in a subject. In some embodiments, the methods include imaging the subject having the glioblastoma using a CEST MRI technique in the absence of introducing an exogenous MRI contrast agent into the subject to produce a test MR image of the subject. In some embodiments, the methods also include identifying an overexpression level of mannose in and / or on surfaces of unlabeled cancer stem cells of the glioblastoma of the subject in the test MR image relative to an identified expression level of mannose in and / or on surfaces of brain cells in a control MR image, wherein a high aggression level is indicated when the overexpression level comprises at least about a 1.8-fold difference and wherein a low aggression level is indicated when the overexpression level comprises less than about a 1.8-fold difference. Related aspects are also provided.

The present invention relates to aptamers that specifically bind to the extra-cellular domain of alpha7 / beta1 integrin dimers, conjugates or particles comprising said aptamers, in muscles cells such as skeletal muscle fibres and satellite cells, or in cells aberrantly expressing said domain e.g. tumour cells such as rhabdomyosarcoma (muscle-derived tumours), or glioblastoma cancer stem cells, as well as conjugates comprising said aptamers, therapeutic or diagnostic compositions comprising said conjugates or said aptamers, and their use as a medicament and in diagnostic methods.

The present invention discloses compounds for inhibiting the proliferation of uncontrolled cells, particularly cancer stem cells. In particular, the present invention relates to compounds of formulas I to IV for treating cancer.

Disclosed herein are macrolide compounds having senescent cell elimination activity. These compounds selectively target senescent cells and can be used to reduce or eradicate senescent cells in a subject's body and / or delay the onset of aging. These compounds also inhibit the proliferation of cancer stem cells and can be used to treat cancer, particularly to inhibit the proliferation of cancer stem cells that cause metastasis and tumor recurrence.

The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC), human induced pluripotent stem cells (hiPSC), somatic stem cells, cancer stem cells, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and / or hiPSC to nociceptors (i.e. nociceptor cells) using novel culture conditions. The nociceptors made using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro drug discovery assays, pain research, and as a therapeutic to reverse disease of, or damage to, the peripheral nervous system (PNS). Further, compositions and methods are provided for producing melanocytes from human pluripotent stem cells for use in disease modeling.

The present invention relates to a composition for the prevention or treatment of cisplatin-resistant cancer comprising an inhibitor of DUSP23 expression or activity as an active ingredient. It was found that DUSP23 expression is upregulated in cell clusters exhibiting characteristics of cancer stem cells, and that knocking down DUSP23 significantly reduces cell cluster formation as well as decreases the expression of SOX2, a major stem cell marker. Furthermore, DUSP23 expression was increased in lung cancer cells that had developed cisplatin resistance, and it was confirmed that the downregulation of DUSP23 inhibits self-renewal and invasive capabilities during the induction of cancer cell death. In addition, it was confirmed that DUSP23 plays an important role in promoting cancer stem cell characteristics through SOX2 expression. In conclusion, it has been shown that targeting DUSP23 can be a promising therapeutic strategy to overcome anticancer drug resistance in lung cancer, and the composition of the present invention is expected to be usefully utilized as a treatment for lung cancer cells with cisplatin resistance.

The present invention relates to a method for treating cancer exhibiting high expression of SFRP4. In particular, the present invention was developed through intensive research to identify a highly reliable treatment method for stem cell-type gastric cancer that has the worst prognosis and for which effective therapeutic agents are difficult to develop. As a result, it was confirmed that the cancer stem cell properties decreased when Wnt protein was injected to the MKN1 gastric cancer cell line, which exhibits high expression of SFRP4. In addition, it was confirmed that secreted frizzled-related protein 4 (SFRP4), phosphorylated and secreted by protein kinase A (PKA) can form a complex with β-catenin and TCF4 to increase transcription of Wnt target genes, and by inhibiting PKA to prevent phosphorylation of SFRP4, a decrease in cancer stem cell properties was observed, which leads to the completion of the present invention. The invention can be advantageously used as a novel therapeutic agent for stem cell-type gastric cancer.

The present disclosure relates generally to compositions and methods for treating cancer. More specifically, the present disclosure relates to compositions and their use in one of altering the transformation of epithelial cells to mesenchymal cells or the transformation of mesenchymal cells to epithelial cells of tumor cells. The method comprises administering to the subject a composition comprising a PI3K inhibitor, such as paxalisib (GDC-0084), and an immunotherapy that is not targeted to cancer stem cells (CSC), wherein the immunotherapy is an immune checkpoint antagonist or a PARP inhibitor.

The present disclosure relates to compositions and methods for reducing cancer stem cells. In some aspects, the compositions and methods can comprise at least one metabolism modulating agent. In other aspects, the compositions and methods can comprise at least two metabolism modulating agents.

The present invention relates to novel antibodies or antigen-binding fragments thereof that specifically bind to TransMembrane 4 Superfamily Member 4 (TM4SF4). These antibodies or antigen-binding fragments thereof exhibit proliferation inhibitory activity of cancer cells so as to effectively prevent or treat cancer, and reduce the self-renewal ability of cancer stem cells to be usefully used even in the treatments of cancer with a poor prognosis in conventional anticancer treatments.

The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6. Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and / or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.

Provided herein are methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an agent that inhibits the activity of ZSCAN4 in cancer cells in the subject, thereby treating the cancer.

The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and / or cancer stem cells) with an antibody that binds to IL3Rα. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3Rα chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and / or managing a disorder associated with IL3Rα-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3Rα.

The invention relates to an application of clofampol in preparation of a medicine for treating gastric cancer, and relates to the technical field of medicines. According to the invention, the new application of the clofampol in preparing the medicine for treating the gastric cancer is provided for the first time, and the medicine exerts the tumor inhibition effect through targeted inhibition of the cell viability of the gastric cancer stem cells and induction of necrotic apoptosis of the gastric cancer stem cells. Besides, the invention provides the application of the combination of the clofampol and the chemotherapeutic drug 5-Fu in preparing the drug for treating the gastric cancer for the first time, so that the use concentration of the chemotherapeutic drug 5-Fu can be reduced, the side effect of the chemotherapeutic drug 5-Fu can be reduced, and the lethality of the chemotherapeutic drug to gastric cancer cells can be greatly enhanced by the combination of the clofampol and the chemotherapeutic drug 5-Fu; the targeting function of the medicine on tumor cells is improved, so that an effective chemotherapy regimen is provided for treating the gastric cancer, the physical and psychological burden of a patient is relieved, the living quality of the patient is improved, and remarkable social benefits and economic benefits are achieved.

The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly cancer stem cells. Particularly, the invention relates to compounds of Formula I to XXII for the treatment of cancer.

Disclosed herein are methods of identifying gastric cancer stem cells or populations of gastric cancer stem cells. Also described herein are methods of isolating one or more gastric cancer stem cells from a population of cells, comprising contacting the cells of the population of cells with an AQP5-binding agent, isolating one or more AQP5-expressing cells bound to the agent, where the one or more AQP5-expressing cells are gastric cancer stem cells. Further described herein are methods of removing or eliminating AQP5 + gastric cancer stem cells as well as methods of treating gastric cancer and methods of monitoring gastric cancer neogenesis or gastric cancer progression.

Synthetic agrimol B and derivatives thereof (“compounds”) that have anticancer properties are disclosed. Methods for synthesizing the compounds with an overall yield ≥7% are disclosed. Pharmaceutical formulations in forms suitable for the delivery of the compounds to a subject in need thereof are disclosed. Methods of using the compounds for treating a cancer, reducing a cancer, or treating or ameliorating one or more symptoms associated with a cancer, such as non-small-cell lung cancer, in a subject are also disclosed. The methods include (i) administering to the subject the pharmaceutical formulation containing one or more compounds, for one or more times. The compounds can selectively kill cancer cells and / or cancer stem cells over noncancerous cells by inducing mitochondria dysfunction and / or inhibiting ER to Golgi trafficking in the cancer cells and / or cancer stem cells.

The present invention relates to a pharmaceutical composition comprising trimebutine as an active ingredient for prevention or treatment of cancer. Having an excellent effect of selectively inhibiting growth and proliferation of cancer stem cells, the pharmaceutical composition can suppress the recurrence, metastasis, and progression of cancer even when used alone. Thus, the composition can be advantageously used as a pharmaceutical composition for prevention or treatment of cancer or in combination with other agents.

The present invention provides compositions and methods for treating or ameliorating advanced cancers, such as drug-resistant or metastatic cancers, or killing cancer stem cells expressing an alpha v beta 3 polypeptide on its cell surface by using a human antibody or a humanized antibody, and the human antibody or humanized antibody is capable of specifically binding to an [alpha] v [beta] 3 (avb3) polypeptide expressed on the cell surface of effector cells such as macrophages, neutrophils and dendritic cells, the Fc region of which has selective affinity for human Fc [gamma] RI (CD64) but does not have selective affinity for other Fc [gamma] R. By administering these antibodies to an individual in need thereof, these human antibodies or humanized antibodies can treat, ameliorate, or slow the progression of advanced cancers or drug resistant cancers or cancers caused, initiated, or maintained by advanced cancers or drug resistant cancer cells or cancer stem cells.

The invention relates to cancer therapy targeting cancer stem cells. Disclosed are compounds, methods, compositions, and kits that allow for the treatment of cancer by, for example, targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. In some embodiments, the cancer is liver cancer, endometrial cancer, leukemia, or multiple myeloma. Compounds used in the present disclosure have formulae (0), (0 ') and (I): # imgabs0 #

To provide compositions and methods for using purified human RNA-editing enzymes.SOLUTION: In alternative embodiments, a method for eradicating or reducing the in vivo number of cancer stem cells is provided, where the method comprises administering an inhibitor of ADAR1 (adenosine deaminase associated with RNA1) to a subject in need thereof, where the ADAR1 inhibitor reduces or significantly reduces ADAR1 Nano-luc reporter activity in cell lines or in human cancer stem cell assays.SELECTED DRAWING: None